サンバイオの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/09/03 | 1,000 | 1,003 | 984 | 996 | ±0 | ±0% | 748,400 |
2024/09/02 | 1,029 | 1,045 | 989 | 996 | -50 | -4.8% | 1,641,700 |
2024/08/30 | 992 | 1,051 | 973 | 1,046 | +51 | +5.1% | 1,591,600 |
2024/08/29 | 989 | 1,012 | 975 | 995 | +5 | +0.5% | 630,100 |
2024/08/28 | 1,004 | 1,007 | 985 | 990 | -21 | -2.1% | 985,500 |
2024/08/27 | 1,037 | 1,037 | 1,003 | 1,011 | -28 | -2.7% | 682,300 |
2024/08/26 | 1,017 | 1,040 | 995 | 1,039 | +28 | +2.8% | 1,035,200 |
2024/08/23 | 1,000 | 1,023 | 992 | 1,011 | +14 | +1.4% | 992,500 |
2024/08/22 | 1,018 | 1,029 | 992 | 997 | -26 | -2.5% | 1,308,500 |
2024/08/21 | 1,074 | 1,086 | 1,022 | 1,023 | -73 | -6.7% | 1,765,400 |
2024/08/20 | 1,031 | 1,100 | 1,020 | 1,096 | +73 | +7.1% | 1,703,100 |
2024/08/19 | 1,015 | 1,130 | 1,010 | 1,023 | +22 | +2.2% | 3,247,100 |
2024/08/16 | 1,041 | 1,049 | 997 | 1,001 | -39 | -3.8% | 1,177,200 |
2024/08/15 | 991 | 1,047 | 983 | 1,040 | +49 | +4.9% | 1,344,500 |
2024/08/14 | 1,006 | 1,012 | 982 | 991 | -18 | -1.8% | 823,200 |
2024/08/13 | 975 | 1,016 | 952 | 1,009 | +34 | +3.5% | 1,116,500 |
2024/08/09 | 1,000 | 1,012 | 945 | 975 | -26 | -2.6% | 1,462,700 |
2024/08/08 | 1,001 | 1,061 | 988 | 1,001 | -12 | -1.2% | 1,400,900 |
2024/08/07 | 980 | 1,054 | 969 | 1,013 | +38 | +3.9% | 2,474,000 |
2024/08/06 | 922 | 975 | 902 | 975 | +150 | +18.2% | 2,449,600 |
2024/08/05 | 943 | 973 | 805 | 825 | -193 | -19% | 3,346,000 |
2024/08/02 | 1,020 | 1,096 | 988 | 1,018 | -92 | -8.3% | 3,421,500 |
2024/08/01 | 1,086 | 1,220 | 1,072 | 1,110 | -6 | -0.5% | 8,629,100 |
2024/07/31 | 978 | 1,116 | 960 | 1,116 | +150 | +15.5% | 7,602,200 |
2024/07/30 | 961 | 1,020 | 933 | 966 | -10 | -1% | 1,872,700 |
2024/07/29 | 1,217 | 1,225 | 966 | 976 | -65 | -6.2% | 6,965,200 |
2024/07/26 | 1,041 | 1,041 | 1,041 | 1,041 | +150 | +16.8% | 110,000 |
2024/07/25 | 904 | 920 | 866 | 891 | -41 | -4.4% | 1,572,600 |
2024/07/24 | 974 | 998 | 932 | 932 | -57 | -5.8% | 1,135,700 |
2024/07/23 | 1,006 | 1,035 | 930 | 989 | -30 | -2.9% | 2,229,300 |
2024/07/22 | 1,032 | 1,057 | 1,012 | 1,019 | -42 | -4% | 1,179,900 |
2024/07/19 | 1,130 | 1,152 | 1,047 | 1,061 | -76 | -6.7% | 1,657,600 |
2024/07/18 | 1,112 | 1,170 | 1,105 | 1,137 | ±0 | ±0% | 1,690,300 |
2024/07/17 | 1,116 | 1,164 | 1,105 | 1,137 | +19 | +1.7% | 2,067,900 |
2024/07/16 | 1,046 | 1,120 | 1,038 | 1,118 | +66 | +6.3% | 1,396,700 |
2024/07/12 | 1,122 | 1,124 | 1,043 | 1,052 | -46 | -4.2% | 1,657,400 |
2024/07/11 | 1,094 | 1,147 | 1,066 | 1,098 | +10 | +0.9% | 3,572,000 |
2024/07/10 | 1,029 | 1,099 | 1,022 | 1,088 | +74 | +7.3% | 3,291,000 |
2024/07/09 | 1,012 | 1,064 | 1,005 | 1,014 | -14 | -1.4% | 2,174,400 |
2024/07/08 | 980 | 1,054 | 978 | 1,028 | +27 | +2.7% | 3,183,900 |
2024/07/05 | 1,133 | 1,137 | 991 | 1,001 | -79 | -7.3% | 5,559,900 |
2024/07/04 | 1,043 | 1,140 | 1,033 | 1,080 | +48 | +4.7% | 6,235,400 |
2024/07/03 | 1,100 | 1,141 | 1,016 | 1,032 | -22 | -2.1% | 4,128,200 |
2024/07/02 | 1,138 | 1,156 | 1,000 | 1,054 | -164 | -13.5% | 8,125,200 |
2024/07/01 | 1,258 | 1,368 | 1,218 | 1,218 | -100 | -7.6% | 9,267,400 |
2024/06/28 | 1,400 | 1,489 | 1,274 | 1,318 | -80 | -5.7% | 25,009,900 |
2024/06/27 | 1,248 | 1,398 | 1,104 | 1,398 | +300 | +27.3% | 12,834,400 |
2024/06/26 | 1,098 | 1,098 | 1,098 | 1,098 | +150 | +15.8% | 316,700 |
2024/06/25 | 843 | 948 | 831 | 948 | +150 | +18.8% | 7,970,500 |
2024/06/24 | 688 | 798 | 687 | 798 | +100 | +14.3% | 12,206,700 |
201~
250
件表示中 / 2500件
類似銘柄と比較する
現在ご覧いただいている「サンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
サンバイオ | 233,200円 | - | - | 0.00% | - | 111.58倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
キッセイ薬 | 401,000円 | +3.6% | +6.1% | 2.99% | 13.51倍 | 0.80倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
鳥居薬 | 632,000円 | +7.1% | -35.0% | 0.00% | 52.26倍 | 1.46倍 |
|
JT傘下。皮膚疾患や腎・透析、花粉症薬などアレルゲン領域に強み。塩野義製薬がTOB実施 |
科研薬 | 379,100円 | -6.4% | -71.8% | 5.01% | 42.34倍 | 0.95倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
ジーエヌアイ | 330,000円 | +21.7% | +999.9% | 0.00% | 13.83倍 | 4.76倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
市場注目の銘柄
チャート関連のコラム